Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT05384405 Recruiting - Clinical trials for Major Depressive Disorder

aiTBS for Relieving NSSI in Depressive Patients

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) in patients with unipolar disorder and bipolar disorder.

NCT ID: NCT05384041 Completed - Clinical trials for Major Depressive Disorder

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

CES-MDD
Start date: April 28, 2022
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

NCT ID: NCT05376150 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

X-NOVA
Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

NCT ID: NCT05366270 Recruiting - Clinical trials for Major Depressive Disorder

Peripheral Neuroimmune Mechanisms of Hyperthermia

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to examine how whole-body hyperthermia affects the thermoinflammatory profile, which includes the combined immune and heat shock response, in patients with depression and whether these changes correlate with decreased depression in individuals with Major Depressive Disorder.

NCT ID: NCT05357040 Recruiting - Clinical trials for Major Depressive Disorder

Antidepressant Effects of Nitrous Oxide

Start date: June 30, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.

NCT ID: NCT05355285 Completed - Clinical trials for Major Depressive Disorder

Type 1 Diabetes and Depression: Role of Brain Glutamate

Start date: January 2011
Phase: N/A
Study type: Interventional

The goal of this study is to examine the effect of chronic and acute hyperglycemia in type 1 diabetes mellitus (T1DM) on brain glutamate levels using magnetic resonance spectroscopy (MRS), and associations of brain glutamate with symptoms of depression.

NCT ID: NCT05353543 Not yet recruiting - Clinical trials for Major Depressive Disorder

Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Acupoints are the stimulus points and reactive points for acupuncture to treat the diseases. Therefore, this study is designed to detect the biological specificity of acupoints in healthy participants and major depressive disorder (MDD) participants by using multiple objective assessment tools. And then acupoints that are statistically different between the two groups will be defined as strong reaction points, and other acupoints without statistically different will be defined as weak response points. In addition, this clinical trial will be conducted to explore whether the efficacy of stimulating strong reaction acupoints is more effective than weak reaction points, thereby confirming the specificity of the acupoint.

NCT ID: NCT05352113 Not yet recruiting - Clinical trials for Major Depressive Disorder

Intradermal Needle Therapy for Major Depressive Disorder

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is a common mental disorder that affects patients' physical health and quality of life. Although traditional acupuncture therapy has certain advantages in improving MDD, there are still some limitations, such as being time-consuming and some people having a fear of acupuncture. Therefore, intradermal needle therapy will be chosen in the treatment of MDD in this study, which is more convenient, shallow needling, and gentle than traditional acupuncture therapy. The study is designed to investigate the therapeutic effect and safety of intradermal needles for MDD.

NCT ID: NCT05347719 Recruiting - Clinical trials for Major Depressive Disorder

Virtual Mindfulness Training for Adults With History of Depression

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Mindfulness Based Cognitive Therapy (MBCT) has shown to be an effective method of preventing relapse of an episode Major Depressive Disorder (MDD). MBCT is a group program that integrates mindfulness skills training with cognitive-behavioral strategies. However, the cost of MBCT is not affordable to many families. The aim of this study is to explore the feasibility and efficacy of an MBCT intervention designed to be delivered at low cost through a virtual delivery format. This study will recruit 240 participants who are in remission from depression and randomize them to an MBCT intervention group or treatment as usual (TAU) for the wait list control group. The wait list control group will complete the intervention after the MBCT intervention group. Assessment administered at pre-intervention (baseline), post-intervention for experimental group, and post-intervention for the wait list control group and follow-up for experimental group. The primary outcome is to test the efficacy of this community-based delivery in reducing depression severity and psychiatric distress in the relapse of an episode of MDD. The secondary outcomes include perceived stress, post-traumatic stress symptoms, adherence to treatment plans not given as part of this study, frequency of relapse of MDD, mindfulness skills, and quality of life. This study will also examine the following potential moderators and correlates of intervention outcomes: comorbid diagnoses, life events history, and MBCT intervention adherence. Finally, the study will examine the following mediators of intervention outcome: mindfulness skills, emotion regulation skills, executive functioning skills, savoring, and positive and negative affect.

NCT ID: NCT05347199 Completed - Clinical trials for Major Depressive Disorder

Effects of a Single Dose of Amisulpride on Functional Brain Changes

Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

This study is designed to investigate effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing and at rest in healthy volunteers (HV) and in patients with Major Depressive Disorder (MDD).